X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress

Sep 30, 2019 at 8:45 AM CEST to Sep 30, 2019 at 9:45 AM CEST

Back to previous page

Investor Contact
Email Alerts
Email Page
Print Page
RSS Feeds